<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402013000400005</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2013.09.001</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Toll-like receptor 4 gene polymorphisms and acute coronary syndrome: No association in a Mexican population]]></article-title>
<article-title xml:lang="es"><![CDATA[No existe asociación entre los polimorfismos del receptor tipo toll-4 y el síndrome coronario agudo]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Ríos]]></surname>
<given-names><![CDATA[Marco A.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas-Alarcón]]></surname>
<given-names><![CDATA[Gilberto]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[Maite]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz-Martinez]]></surname>
<given-names><![CDATA[Erick]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Méndez]]></surname>
<given-names><![CDATA[Oscar]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina-Andrade]]></surname>
<given-names><![CDATA[Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[De la Torre-García]]></surname>
<given-names><![CDATA[Mónica]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peña-Duque]]></surname>
<given-names><![CDATA[Marco A.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fragoso]]></surname>
<given-names><![CDATA[José Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Interventional Cardiology ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Department of Molecular Biology and Interventional Genetic Study Group in Cardiovascular Disease's ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Department of Sociomedicine ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2013</year>
</pub-date>
<volume>83</volume>
<numero>4</numero>
<fpage>257</fpage>
<lpage>262</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402013000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402013000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402013000400005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Objective: The objective of this study was to establish the role of the TLR-4 gene polymorphisms in individuals in risk of developing ACS. Methods: The study included 457 Mexican patients with ACS and 283 control individuals. The TLR-4 Asp299Gly and TLR-4 Thr399Ile single nucleotide polymorphisms were genotyped using 5' exonuclease TaqMan genotyping assays on an 7900HT Fast real-time PCR system according to manufacturer's instructions (Applied Biosystems, Foster City, USA). Results: The results obtained in this study showed that the frequency of the two polymorphisms (TLR-4 Asp299Gly and TLR-4 Thr399Ile) studied were similar between patients with ACS and healthy controls. Multiple logistic regression analysis showed that the largest risk factor for ACS development was given by smoking (11.88-fold increased risk), hypertension (4.32-fold increased risk), type II diabetes (3.44-fold increased risk), gender (2.32-fold increased risk), and dyslipidemia (1.52-fold increased risk). Conclusion: The Asp299Gly and Thr399Ile polymorphisms were not associated with susceptibility to ACS in the Mexican population.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Objetivo: El objetivo de este estudio fue establecer el papel de los polimorfismos del gen TLR-4 en individuos en riesgo de desarrollar síndrome coronario agudo (SCA). Métodos: El estudio incluyó a 457 pacientes mexicanos con SCA y 283 individuos como grupo control. Los polimorfismos de un solo nucleótido TLR-4 Asp299Gly y TLR-4 Thr399Ile fueron determinados usando ensayos TaqMan 5' exonucleasa en un equipo tiempo real 7900HT (Fast real-time PCR system) de acuerdo con instrucciones del fabricante Applied Biosystems, Foster City, EE.UU. Resultados: Los resultados obtenidos mostraron que las frecuencias de los 2 polimorfismos (TLR-4Asp299Gly y TLR-4 Thr399Ile) estudiados fueron similares entre pacientes con SCA e individuos control. No obstante, el análisis de regresión logística mostró que los factores de mayor riesgo para desarrollar SCA se debieron a tabaquismo (incrementa 11.88 veces el riesgo), hipertensión (incrementa 4.32 veces el riesgo), diabetes tipo 2 (incrementa 3.44 veces el riesgo), género (incrementa 2.32 veces el riesgo), y la dislipidemia (incrementa 1.52 veces el riesgo). Conclusión: Determinamos que los polimorfismos Asp299Gly y Thr399Ile no se asocian con la susceptibilidad al SCA en la población mexicana.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Single nucleotide polymorphisms]]></kwd>
<kwd lng="en"><![CDATA[Acute coronary syndrome]]></kwd>
<kwd lng="en"><![CDATA[Genetics]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
<kwd lng="es"><![CDATA[Polimorfismos de un nucleótido]]></kwd>
<kwd lng="es"><![CDATA[Síndrome coronario agudo]]></kwd>
<kwd lng="es"><![CDATA[Genética]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[  	    <p align="justify"><font face="verdana" size="4">Investigaci&oacute;n cl&iacute;nica</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="center"><font face="verdana" size="4"><b>Toll&#45;like receptor 4 gene polymorphisms and acute coronary syndrome: No association in a Mexican population</b></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="center"><font face="verdana" size="3"><b>No existe asociaci&oacute;n entre los polimorfismos del receptor tipo toll&#45;4 y el s&iacute;ndrome coronario agudo</b></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="center"><font face="verdana" size="2"><b>Marco A. Mart&iacute;nez&#45;R&iacute;os<sup>a</sup>, Gilberto Vargas&#45;Alarc&oacute;n<sup>b</sup>, Maite Vallejo<sup>c</sup>, Erick Cruz&#45;Martinez<sup>a</sup>, Oscar P&eacute;rez&#45;M&eacute;ndez<sup>b</sup>, &Aacute;ngel Medina&#45;Andrade<sup>b</sup>, M&oacute;nica De la Torre&#45;Garc&iacute;a<sup>b</sup>, Marco A. Pe&ntilde;a&#45;Duque<sup>a</sup>, Jos&eacute; Manuel Fragoso<sup>b</sup>*</b></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><sup><i>a</i></sup> <i>Interventional Cardiology, Instituto Nacional de Cardiolog&iacute;a Ignacio Ch&aacute;vez, Mexico City, Mexico.</i></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><i><sup>b</sup> Department of Molecular Biology and Interventional Genetic Study Group in Cardiovascular Disease's, Instituto Nacional de Cardiolog&iacute;a Ignacio Ch&aacute;vez, Mexico City, Mexico.</i></font></p>  	    <p align="justify"><font face="verdana" size="2"><i><sup>c</sup> Department of Sociomedicine, Instituto Nacional de Cardiolog&iacute;a Ignacio Ch&aacute;vez, Mexico City, Mexico.</i></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>* Corresponding author:</b>    <br> 	Juan Badiano No. 1, Tlalpan 14080, M&eacute;xico DF, Mexico.    <br> 	Tel.: +52 55 5573 2911x1460; fax: +52 55 5573 0926.<i>    <br> 	E&#45;mail address:</i> <a href="mailto:mfragoso1275@yahoo.com.mx">mfragoso1275@yahoo.com.mx</a> (J.M. Fragoso).</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2">Received 27 November 2012.    <br> 	Accepted 9 September 2013.</font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Abstract</b></font></p>  	    <p align="justify"><font face="verdana" size="2"><i><b>Objective:</b></i> The objective of this study was to establish the role of the TLR&#45;4 gene polymorphisms in individuals in risk of developing ACS.</font></p>  	    <p align="justify"><font face="verdana" size="2"><i><b>Methods:</b></i> The study included 457 Mexican patients with ACS and 283 control individuals. The TLR&#45;4 Asp299Gly and TLR&#45;4 Thr399Ile single nucleotide polymorphisms were genotyped using 5' exonuclease TaqMan genotyping assays on an 7900HT Fast real&#45;time PCR system according to manufacturer's instructions (Applied Biosystems, Foster City, USA).</font></p>  	    <p align="justify"><font face="verdana" size="2"><i><b>Results:</b></i> The results obtained in this study showed that the frequency of the two polymorphisms (TLR&#45;4 Asp299Gly and TLR&#45;4 Thr399Ile) studied were similar between patients with ACS and healthy controls. Multiple logistic regression analysis showed that the largest risk factor for ACS development was given by smoking (11.88&#45;fold increased risk), hypertension (4.32&#45;fold increased risk), type II diabetes (3.44&#45;fold increased risk), gender (2.32&#45;fold increased risk), and dyslipidemia (1.52&#45;fold increased risk).</font></p>  	    <p align="justify"><font face="verdana" size="2"><i><b>Conclusion:</b></i> The Asp299Gly and Thr399Ile polymorphisms were not associated with susceptibility to ACS in the Mexican population.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Keywords:</b> Single nucleotide polymorphisms; Acute coronary syndrome; Genetics; Mexico.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Resumen</b></font></p>  	    <p align="justify"><font face="verdana" size="2"><i><b>Objetivo:</b></i> El objetivo de este estudio fue establecer el papel de los polimorfismos del gen <i>TLR&#45;4</i> en individuos en riesgo de desarrollar s&iacute;ndrome coronario agudo (SCA).</font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><i><b>M&eacute;todos:</b></i> El estudio incluy&oacute; a 457 pacientes mexicanos con SCA y 283 individuos como grupo control. Los polimorfismos de un solo nucle&oacute;tido <i>TLR&#45;4 Asp299Gly</i> y <i>TLR&#45;4 Thr399Ile</i> fueron determinados usando ensayos TaqMan 5' exonucleasa en un equipo tiempo real 7900HT (Fast real&#45;time PCR system) de acuerdo con instrucciones del fabricante Applied Biosystems, Foster City, EE.UU.</font></p>  	    <p align="justify"><font face="verdana" size="2"><i><b>Resultados:</b></i> Los resultados obtenidos mostraron que las frecuencias de los 2 polimorfismos <i>(TLR&#45;4Asp299Gly</i> y <i>TLR&#45;4 Thr399Ile)</i> estudiados fueron similares entre pacientes con SCA e individuos control. No obstante, el an&aacute;lisis de regresi&oacute;n log&iacute;stica mostr&oacute; que los factores de mayor riesgo para desarrollar SCA se debieron a tabaquismo (incrementa 11.88 veces el riesgo), hipertensi&oacute;n (incrementa 4.32 veces el riesgo), diabetes tipo 2 (incrementa 3.44 veces el riesgo), g&eacute;nero (incrementa 2.32 veces el riesgo), y la dislipidemia (incrementa 1.52 veces el riesgo).</font></p>  	    <p align="justify"><font face="verdana" size="2"><i><b>Conclusi&oacute;n:</b></i> Determinamos que los polimorfismos <i>Asp299Gly</i> y <i>Thr399Ile</i> no se asocian con la susceptibilidad al SCA en la poblaci&oacute;n mexicana.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Palabras clave:</b> Polimorfismos de un nucle&oacute;tido; S&iacute;ndrome coronario agudo; Gen&eacute;tica; M&eacute;xico.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Introduction</b></font></p>  	    <p align="justify"><font face="verdana" size="2">Atherosclerosis is a multifactorial disorder that results from an excessive inflammatory response to various forms of injurious stimuli to the arterial wall.<sup>1&#45;3</sup> The inflammatory processes, genetic background, and various environmental factors, coupled to dyslipidemia, including hypertension, diabetes, obesity, and smoking play an important role in the progression of the atherosclerotic plaque.<sup>3&#45;5</sup> The transition of a stable coronary atherosclerotic lesion into a ruptured and eroded plaque results in the clinical manifestation of an acute coronary syndrome (ACS).<sup>5,6</sup> The ACS includes unstable angina and myocardial infarction caused mainly by rupture or erosion of the atherosclerotic plaque, with subsequent thrombus formation.<sup>6&#45;8</sup> Mounting evidence suggests that specific agents enhance arterial inflammation during atherogenesis, based on their interaction with receptor signaling pathways of the innate immune systems.<sup>9,10</sup> Toll&#45;like receptor 4 <i>(TLR&#45;4)</i> is part of the innate immunity response cascade. It has been associated as one of the factors contributing to the deleterious process of atherosclerosis.<sup>11&#45;13</sup> <i>TLR&#45;4</i> is well known as a pattern&#45;recognition receptor for exogenous lipopolysacharide (LPS) derived from gram&#45;negative bacterial infection.<sup>14,15</sup> However, several studies showed that <i>TLR&#45;4</i> interacts with other ligands, such as fibrinogen,<sup>16</sup> fibronectin,<sup>17</sup> heat&#45;shock protein,<sup>18</sup> hyaluronan oligosaccharide<sup>19</sup> and modified low&#45;density lipoproteins (LDL),<sup>20,21</sup> playing an important role in the development of the atherosclerotic plaque. The <i>TLR&#45;4</i> gene is located in the 9q32 region.<a href="#bookmark16"><sup>15</sup></a> <i>TLR&#45;4</i> presents two single nucleotide polymorphisms (SNP), both polymorphisms, rs4986790 <i>(Asp299Gly)</i> and rs4986791 <i>(Thr399Ile),</i> are located in the coding region. These (SNPs) affect <i>TLR&#45;4</i> extracellular domain and result in amino acid exchanges: an aspartic acid for a glycine at position 299 <i>(Asp299Gly)</i> and a threonine for a isoleucine at position 399 <i>(Thr399Ile).</i><sup>11,13</sup></font></p>  	    <p align="justify"><font face="verdana" size="2">Several studies associate these polymorphisms with several inflammatory diseases, such as ACS, gastric cancer, carotid artery elasticity, chronic obstructive pulmonary disease, and atherosclerosis.<sup>24&#45;28</sup> Considering the prominent role of the <i>TLR&#45;4</i> as initiator of the inflammatory response, this study was based on the assumption that the <i>TLR&#45;4</i> gene polymorphisms have a measurable influence in the development of the atherosclerotic plaque and contributes to or increases the occurrence of ACS. The objective of this study was to establish the possible role of the <i>TLR&#45;4</i> gene polymorphisms as a risk factor for ACS in a group of Mexicans patients.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Methods</b></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><b>Study populations</b></font></p>  	    <p align="justify"><font face="verdana" size="2">The study included 457 Mexican patients with ACS (368 males and 89 females, mean age 59.7 &plusmn; 11.02) that were attended to our Institution. Three hundred forty&#45;two presented myocardial infarction and 115 presented unstable angina. All subjects were diagnosed according to the World Health Organization and the American Heart Associated (AHA)/American College of Cardiology (ACC).<sup>29</sup> Basis in clinical history, physical examination with electrocardiography, chest radiography, echocardiography, and coronary angiography. The group of patients was compared with a group of 283 healthy unrelated individuals (202 males and 81 females, mean age 55.39 &plusmn; 7.23). This group was selected from people arriving with the purpose to donation at the blood bank at our institute. According to the medical records, none of these had diabetes, dyslipidemia, hypertension or other pathology. On the other hand, subclinical atherosclerosis was discarded through determined calcium score by multi&#45;detector computed tomography. The values were zero in these individuals. All subjects included in the study (patients and controls) were ethnically matched, and we considered as Mexican Mestizos only those individuals who had been born in Mexico for three generations, including their own. A Mexican Mestizo is defined as someone born in Mexico, who is a descendant of the original autochthonous inhabitants of the region and of individuals, mainly Spaniards, of Caucasian and African origin, who came to the American continent during the sixteenth century. The Institutional Ethics and Research Committees approved the study, and all subjects provided written, informed consent.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>DNA extraction</b></font></p>  	    <p align="justify"><font face="verdana" size="2">Genomic DNA from whole blood containing EDTA was isolated with a standard technique.<sup>30</sup></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Determination of the TLR&#45;4 genotypes</b></font></p>  	    <p align="justify"><font face="verdana" size="2">The <i>TLR&#45;4 Asp299Gly</i> (rs4986790) and <i>TLR&#45;4 Thr399Ile</i> (rs4986791) single nucleotide polymorphisms were geno&#45;typed using 5' exonuclease TaqMan genotyping assays on an 7900HT Fast real&#45;time PCR system according to manufacturer's instructions (Applied Biosystems, Foster City, USA).</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Statistical analysis</b></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2">Gene frequencies of <i>TLR&#45;4</i> polymorphisms in patients and controls were obtained by direct counting. Hardy&#45;Weinberg equilibrium was evaluated by Chi<sup>2</sup> test. Statistical analysis was carried out with the Stata 10.0 software for Windows. In the exploratory analysis, numerical data showed a different distribution from normal standard (Gaussian distribution) (Shapiro Wilk's test of normality, <i>p</i> &gt;0.05), nominal and categorical variables were tabulated to estimate their proportions. Hypertension, altered lipid profile, smoking, and type 2 diabetes mellitus had two categories, yes or no, and all described the current condition of patients and healthy controls. Comparison of numerical variables, such as age and body mass index, between both groups was carried out with Mann&#45;Whitney <i>U</i> test, data are presented as the 25th percentile, median, and 75th percentile. Categorical variables were analyzed with Chi<sup>2</sup> tests and presented as absolute frequencies and proportions. Statistical significance was set at <i>p</i> &#8804; 0.05. Multiple logistic regression analysis was carried out to identify the variables that better explain the risk of developing ACS between patients and healthy controls. Models were constructed including one variable at a time to identify confounding bias; changes in estimated odds ratios (ORs) were less than 10%. When a main effect model was reached, effect modification was also tested, interaction terms were constructed between age and BMI, hypertension and type 2 diabetes mellitus, smoking and hypertension, and gender and BMI, no significant ORs (<i>p</i> &#8804; 0.20) were identified and therefore these terms were not included in the final model. Hosmer&#45;Lemeshow Goodness of fit test was performed for each multiple logistic model. Pairwise linkage disequilibrium (LD, D ) estimations between polymorphisms and haplotype reconstruction were performed with Haploview version 4.1 (Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA).</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Results</b></font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Characteristic of the study sample</b></font></p>  	    <p align="justify"><font face="verdana" size="2">Baseline characteristic of the ACS patients and healthy controls included in the study are shown in <a href="/img/revistas/acm/v83n4/a5t1.jpg" target="_blank">Table 1</a>.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Allele and genotype frequencies</b></font></p>  	    <p align="justify"><font face="verdana" size="2">The observed and expected frequencies in the two polymorphic sites of the toll&#45;like receptor (<i>TLR&#45;4</i>) were in Hardy&#45;Weinberg equilibrium. The allele and genotype frequencies of the two studied polymorphisms (positions +896 <i>A&gt;G</i> (<i>Asp299Gly</i>) and +1196 <i>C&gt;T</i> (<i>Thr399Ile</i>)) were similar between patients with ACS and healthy controls (<a href="/img/revistas/acm/v83n4/a5t2.jpg" target="_blank">Table 2</a>). The multiple logistic regression analysis showed that the largest risk for ACS development was given by smoking (11.88&#45;fold increased risk), hypertension (4.32&#45;fold increased risk), type II diabetes (3.44&#45;fold increased risk), gender (2.32&#45;fold increased risk), and dyslipidemia (1.52&#45;fold increased risk) (<a href="/img/revistas/acm/v83n4/a5t3.jpg" target="_blank">Table 3</a>). The +896 <i>A&gt;G (Asp299Gly)</i> and +1196 <i>C&gt;T</i> (<i>Thr399Ile</i>) polymorphisms showed a strong linkage disequilibrium (<i>D</i> = 0.82) and were used to construct two haplotypes (AC and <i>GT).</i> The haplotype <i>"AC"</i> showed a similar distribution in ACS patients and healthy controls (95.7% and 96.8%, respectively). Moreover, the <i>"GT"</i> haplotype showed a similar decreased in patients and control (4.3%, and 3.2%, respectively).</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Discussion</b></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2">In the present work, we studied two polymorphisms (<i>Asp299Gly</i> and <i>Thr399Ile</i>) located in the <i>TLR&#45;4</i> gene in 457 patients with ACS and 283 healthy controls. In humans, both polymorphisms affect <i>TLR&#45;4</i> extracellular domain and individuals that possess these polymorphisms are hypore&#45;sponsive to several ligands.<sup>11&#45;13</sup> In this study, we observed that the distribution of the two polymorphisms were similar in patients with ACS and healthy controls. The association of the <i>TLR&#45;4</i> gene polymorphisms with several diseases in different populations is controversial with positive and negative results. For example, Koch et al. reported no association of the two <i>TLR&#45;4</i> gene polymorphisms with myocardial infarction in 3647 patients and 1211 individuals control with angiographic normal coronary and without signs or symptoms of myocardial infarction. In this work the authors showed that gender (women and men) did not sex&#45;related associations and genotypes of polymorphisms in a Caucasian population,<sup>31</sup> agreeing with our results. Similar data were obtained by Labrum et al. who studied the two <i>TLR&#45;4</i> gene polymorphisms in a cohort 3000 individuals obtained of carotid atherosclerosis progression study. In this study showed no association between carotid artery intima&#45;media thickness and polymorphisms of the TLR4 gene in 1460 males and 1540 females. However, there was no association between polymorphisms of TLR4 gene and baseline intima&#45;media thickness. In addition, is reported there was no interactions between polymorphisms and the cardiovascular risk factors (C&#45;reactive protein, smoking, body mass index and diabetes) in Caucasian population.<sup>32</sup> Moreover, Zee et al. reported that the <i>Asp299Gly</i> polymorphism is not associated with risk of incident myocardial infarction and stroke in 695 patients and 695 individuals control matched by age, smoking history, adjusted by body mass index, history of hypertension and presence or absence of diabetes, in a US population,<sup>33</sup> in line with our data. In contrast with these results, Ameziane et al. reported that the <i>299Gly</i> allele is associated with decreased risk of developing ACS in 183 patients and 216 controls (OR = 0.41). In addition, in controls the individuals with heterozygous (299 Asp/Gly) genotype was also associated with a significantly decrease in plasma fibrinogen and soluble vascular cellular adhesion molecule&#45;1 levels in a French population.<sup>24</sup> On the other hand, Hernesniemi et al. reported an association of the <i>299Gly</i> allele with increased carotid artery elasticity in a cohort of 2201 young adults. In addition, according to multivariate linear regression analysis adjusted with potential confounders, the 299<i>Gly</i> allele carriers had significantly higher carotid arterial compliance, measured in increase of luminal diameter percentage in response to blood pressure. This increase has beneficial effects, because it reduces the risk of future cardiovascular events.<sup>25</sup> Santini et al. reported in a case&#45;control study that the <i>CT</i> (<i>Thr/Ile</i>) genotype of the <i>Thr388Ile</i> polymorphism increases susceptibility to gastric cancer (OR = 5.38). In addition, according with regression analysis determine that the <i>Thr/Ile</i> genotype adjusted for age, sex (male), alcohol intake and smoking status increases susceptibility to gastric cancer (OR = 3.62).<sup>26</sup> Similar data were reported by Speletas et al., who observed that the <i>T (Ile)</i> allele and <i>CT (Thr/Ile)</i> genotype (OR = 2.4 and OR = 2.0, respectively) are associated with risk of developing chronic obstructive pulmonary disease in a case &#45;control study. Unfortunately, authors no determine differences between polymorphism and clinical and demographic data.<sup>27</sup> Nonetheless, the results obtained of the multiple logistic regression analysis showed that smoking, hypertension, type II diabetes, and gender increased more the risk of developing ACS. These data confirm the previous results obtained by our group in a small group of patients.<sup>34</sup> Moreover, this analysis showed no association between the <i>TLR4</i> gene polymorphisms and clinical characteristics of the ACS in Mexican patients.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Limitations of the study</b></font></p>  	    <p align="justify"><font face="verdana" size="2">We recognize that our study has limitations; one was the limited samples number in controls group. Another limitation was pairing by gender between patients group and control group. Some experts consider that a proper analysis would need a relation between controls and patients of 1:1. Unfortunately for this report we could not meet this criterion. Nonetheless, the results from the present study are concordant with data reported in the international literature.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Conclusion</b></font></p>  	    <p align="justify"><font face="verdana" size="2">The <i>Asp299Gly</i> and <i>Thr399Ile</i> gene polymorphisms were not associated with ACS in the present group of Mexican patients.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Funding</b></font></p>  	    <p align="justify"><font face="verdana" size="2">This work was supported in part by grants from the <i>Consejo Nacional de Ciencia y Tecnolog&iacute;a</i> (project 156911) and <i>Fundaci&oacute;n Gonzalo Rio Arronte,</i> Mexico City, Mexico.</font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Disclosure</b></font></p>  	    <p align="justify"><font face="verdana" size="2">The authors alone are responsible for the content and writing of the paper.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Conflicts of interest</b></font></p>  	    <p align="justify"><font face="verdana" size="2">The authors report no conflicts of interest.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Acknowledgment</b></font></p>  	    <p align="justify"><font face="verdana" size="2">The authors are grateful to the study participants.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><b>References</b></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">1. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 1999;340:115&#45;26.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123603&pid=S1405-9940201300040000500001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">2. Garcia&#45;Moll X. Inflammatory and anti&#45;inflammatory markers in acute coronary syndromes. Ready for use in the clinical setting? Rev Esp Cardiol. 2005;58:615&#45;7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123605&pid=S1405-9940201300040000500002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">3. Lusis AJ. Atherosclerosis. Nature. 2000;407:233&#45;41.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123607&pid=S1405-9940201300040000500003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">4. Libby P. Inflammation and atherosclerosis. Nature. 2002;420:868&#45;74.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123609&pid=S1405-9940201300040000500004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">5. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Thromb Vasc Biol. 2005;25:2054&#45;61.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123611&pid=S1405-9940201300040000500005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">6. Achar SA, Kundu S, Norcroos WA. Diagnosis of acute coronary syndromes. Am Fam Physician. 2005;72:119&#45;26.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123613&pid=S1405-9940201300040000500006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">7. Mouco OM, Nicolau JC, Souza T, de R, et al. Inflammatory markers of atherosclerotic plaque stabilization after acute coronary event&#45;temporal trends. Arq Bras Cardiol. 2005;87:28&#45;36.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123615&pid=S1405-9940201300040000500007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">8. Malarstig A, Eriksson P, Hamsten A, et al. Raised interleukin&#45;10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart. 2006;94:724&#45;9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123617&pid=S1405-9940201300040000500008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">9. Schwartz DA. The genetics of innate immunity. Chest. 2002;121:562&#45;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123619&pid=S1405-9940201300040000500009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">10. Schroder NW, Schumann RR. Single nucleotide polymorphisms of toll&#45;like receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005;5:156&#45;64.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123621&pid=S1405-9940201300040000500010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">11. Michelsen KS, Doherty TM, Shah PK, et al. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol. 2004;173:5801&#45;907.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123623&pid=S1405-9940201300040000500011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">12. Pastekamp G, VanKuelem JK, De Kleijn DP. Role of toll&#45;like receptors 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest. 2004;34:328&#45;34.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123625&pid=S1405-9940201300040000500012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">13. Michelsen KS, Doherty TM, Shah PK, et al. Role of toll&#45;like receptors in atherosclerosis. Circ Res. 2004;95:e97.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123627&pid=S1405-9940201300040000500013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">14. Poltorak A, He X, Smirnova I, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085&#45;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123629&pid=S1405-9940201300040000500014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">15. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187&#45;91.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123631&pid=S1405-9940201300040000500015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">16. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll&#45;like receptor 4. J Immunol. 2001;167:2887&#45;94.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123633&pid=S1405-9940201300040000500016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">17. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates toll&#45;like receptor 4. J Biol Chem. 2001;276:10229&#45;33.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123635&pid=S1405-9940201300040000500017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">18. Ohashi K, Burkart V, Flohe S, et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll&#45;like receptor&#45;4 complex. J Immunol. 2000;164:558&#45;61.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123637&pid=S1405-9940201300040000500018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">19. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via toll&#45;like receptor 4. J Exp Med. 2002;195:99&#45;111.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123639&pid=S1405-9940201300040000500019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">20. Xu XH, Shah PK, Faure E, et al. Toll&#45;like receptor&#45;4 is expressed by macrophages in murine and human lipid&#45;rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103&#45;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123641&pid=S1405-9940201300040000500020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">21. Miller YI, Viriyakosol S, Binder CJ, et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD&#45;2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 2003;278:1561&#45;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123643&pid=S1405-9940201300040000500021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">22. Mockenhaupt FP, Cramer JP, Hamann L, et al. Toll&#45;like receptor (TLR) polymorphisms in African children: common TLR&#45;4 variants predispose to severe malaria. J Commun Dis. 2006;38:230&#45;45.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123645&pid=S1405-9940201300040000500022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">23. Achyut BR, Ghoshal UC, Moorchung N, et al. Association of toll&#45;like receptor&#45;4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol. 2007;68:901 &#45;7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123647&pid=S1405-9940201300040000500023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">24. Ameziane N, Beillat T, Verpillat P, et al. Association of the toll&#45;like recptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol. 2003;23:e61 &#45;4.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123649&pid=S1405-9940201300040000500024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">25. Hernesniemi JA, Raitakari OT, Kahonen M, et al. Toll&#45;like receptor 4 gene (Asp299Gly) polymorphism associates with carotid artery elasticity the cardiovascular risk in young Finns study. Atherosclerosis. 2008;198:152&#45;9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123651&pid=S1405-9940201300040000500025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">26. Santini D, Angeletti S, Ruzzo AA, et al. Toll&#45;like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol. 2008;154:360&#45;4.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123653&pid=S1405-9940201300040000500026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">27. Speletas M, Merentiti V, Kostikas K, et al. Association of TLR4&#45;T399I polymorphism with chronic obstructive pulmonary disease in smokers. Clin Dev Immunol. 2009 &#91;ID: 260286; Epub ahead of print&#93;    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123655&pid=S1405-9940201300040000500027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->.</font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">28. Kiechl S, Lorenz E, Reindl M, et al. Toll&#45;like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185&#45;92.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123657&pid=S1405-9940201300040000500028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">29. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841&#45;2.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123659&pid=S1405-9940201300040000500029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">30. Lahiri DK, Numberger Jr JI. A rapid non&#45;enzymatic method for the preparation HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123661&pid=S1405-9940201300040000500030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">31. Koch W, Hoppmann P, Pfeufer A, et al. Toll&#45;like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. Eur Heart J. 2006;27:2524&#45;9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123663&pid=S1405-9940201300040000500031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">32. Labrum R, Bevan S, Sitzer M, et al. Toll receptor polymorphisms and carotid artery intima&#45;media thickness. Stroke. 2007;38:1179&#45;84.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123665&pid=S1405-9940201300040000500032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">33. Zee R, Hegener HH, Gould J, et al. Toll&#45;like receptor 4 Asp299Gly gene polymorphism and risk of atherosclerosis. Stroke. 2005;36:154&#45;7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123667&pid=S1405-9940201300040000500033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">34. Fragoso JM, Vallejo M, Alvarez&#45;Leon E, et al. Alleles and haplotypes of the interleukin 10 gene polymorphisms are associated with risk of developing acute coronary syndrome in Mexican patients. Cytokine. 2011;55:29&#45;33.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1123669&pid=S1405-9940201300040000500034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Atherosclerosis an inflammatory disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>340</volume>
<page-range>115-26</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia-Moll]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inflammatory and anti-inflammatory markers in acute coronary syndromes. Ready for use in the clinical setting?]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2005</year>
<volume>58</volume>
<page-range>615-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lusis]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Atherosclerosis]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2000</year>
<volume>407</volume>
<page-range>233-41</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Libby]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inflammation and atherosclerosis]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2002</year>
<volume>420</volume>
<page-range>868-74</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Virmani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kolodgie]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage]]></article-title>
<source><![CDATA[Thromb Vasc Biol]]></source>
<year>2005</year>
<volume>25</volume>
<page-range>2054-61</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Achar]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Kundu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Norcroos]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnosis of acute coronary syndromes]]></article-title>
<source><![CDATA[Am Fam Physician]]></source>
<year>2005</year>
<volume>72</volume>
<page-range>119-26</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mouco]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolau]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[de]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inflammatory markers of atherosclerotic plaque stabilization after acute coronary event-temporal trends]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2005</year>
<volume>87</volume>
<page-range>28-36</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malarstig]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hamsten]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2006</year>
<volume>94</volume>
<page-range>724-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The genetics of innate immunity]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2002</year>
<volume>121</volume>
<page-range>562-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schroder]]></surname>
<given-names><![CDATA[NW]]></given-names>
</name>
<name>
<surname><![CDATA[Schumann]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Single nucleotide polymorphisms of toll-like receptors and susceptibility to infectious disease]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2005</year>
<volume>5</volume>
<page-range>156-64</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michelsen]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Doherty]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[TLR signaling: an emerging bridge from innate immunity to atherogenesis]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2004</year>
<volume>173</volume>
<page-range>5801-907</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pastekamp]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[VanKuelem]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[De Kleijn]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Role of toll-like receptors 4 in the initiation and progression of atherosclerotic disease]]></article-title>
<source><![CDATA[Eur J Clin Invest]]></source>
<year>2004</year>
<volume>34</volume>
<page-range>328-34</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michelsen]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Doherty]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Role of toll-like receptors in atherosclerosis]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2004</year>
<volume>95</volume>
<page-range>e97</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poltorak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Smirnova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Smirnova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene]]></article-title>
<source><![CDATA[Science]]></source>
<year>1998</year>
<volume>282</volume>
<page-range>2085-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbour]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schutte]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[TLR4 mutations are associated with endotoxin hyporesponsiveness in humans]]></article-title>
<source><![CDATA[Nat Genet]]></source>
<year>2000</year>
<volume>25</volume>
<page-range>187-91</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smiley]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Hancock]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2001</year>
<volume>167</volume>
<page-range>2887-94</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okamura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Watari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jerud]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The extra domain A of fibronectin activates toll-like receptor 4]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>2001</year>
<volume>276</volume>
<page-range>10229-33</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Burkart]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Flohe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2000</year>
<volume>164</volume>
<page-range>558-61</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Termeer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Benedix]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sleeman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4]]></article-title>
<source><![CDATA[J Exp Med]]></source>
<year>2002</year>
<volume>195</volume>
<page-range>99-111</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[XH]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Faure]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2001</year>
<volume>104</volume>
<page-range>3103-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[YI]]></given-names>
</name>
<name>
<surname><![CDATA[Viriyakosol]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Binder]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>2003</year>
<volume>278</volume>
<page-range>1561-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mockenhaupt]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<name>
<surname><![CDATA[Cramer]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Hamann]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria]]></article-title>
<source><![CDATA[J Commun Dis.]]></source>
<year>2006</year>
<volume>38</volume>
<page-range>230-45</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Achyut]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Ghoshal]]></surname>
<given-names><![CDATA[UC]]></given-names>
</name>
<name>
<surname><![CDATA[Moorchung]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Association of toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions]]></article-title>
<source><![CDATA[Hum Immunol]]></source>
<year>2007</year>
<volume>68</volume>
<page-range>901 -7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ameziane]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Beillat]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Verpillat]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Association of the toll-like recptor 4 gene Asp299Gly polymorphism with acute coronary events]]></article-title>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>2003</year>
<volume>23</volume>
<page-range>e61 -4</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernesniemi]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Raitakari]]></surname>
<given-names><![CDATA[OT]]></given-names>
</name>
<name>
<surname><![CDATA[Kahonen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Toll-like receptor 4 gene (Asp299Gly) polymorphism associates with carotid artery elasticity the cardiovascular risk in young Finns study]]></article-title>
<source><![CDATA[Atherosclerosis]]></source>
<year>2008</year>
<volume>198</volume>
<page-range>152-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Angeletti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ruzzo]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes]]></article-title>
<source><![CDATA[Clin Exp Immunol]]></source>
<year>2008</year>
<volume>154</volume>
<page-range>360-4</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Speletas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Merentiti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kostikas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Association of TLR4-T399I polymorphism with chronic obstructive pulmonary disease in smokers]]></article-title>
<source><![CDATA[Clin Dev Immunol]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiechl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Reindl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Toll-like receptor 4 polymorphisms and atherogenesis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>347</volume>
<page-range>185-92</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Bristow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1996</year>
<volume>93</volume>
<page-range>841-2</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lahiri]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Numberger Jr]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A rapid non-enzymatic method for the preparation HMW DNA from blood for RFLP studies]]></article-title>
<source><![CDATA[Nucleic Acids Res]]></source>
<year>1991</year>
<volume>19</volume>
<page-range>5444</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koch]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hoppmann]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeufer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2006</year>
<volume>27</volume>
<page-range>2524-9</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Labrum]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bevan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sitzer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Toll receptor polymorphisms and carotid artery intima-media thickness]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2007</year>
<volume>38</volume>
<page-range>1179-84</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zee]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hegener]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Gould]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherosclerosis]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2005</year>
<volume>36</volume>
<page-range>154-7</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fragoso]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez-Leon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Alleles and haplotypes of the interleukin 10 gene polymorphisms are associated with risk of developing acute coronary syndrome in Mexican patients]]></article-title>
<source><![CDATA[Cytokine]]></source>
<year>2011</year>
<volume>55</volume>
<page-range>29-33</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
